Vaxil’s immunotherapies are able to efficiently overcome difficulties posed by immune evade mechanisms utilized by cancer, mainly Transporter Associated Antigen Processing (TAP) deficiency which is often mediated by cancer cells and pathogens. To the best of our knowledge, Vaxil’s are the only products which currently possess this crucial characteristic.
VAXIL – Creating the ideal immunotherapy
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is its ImMucin™ lead immunotherapy product.